The Institute for Research in Biomedicine, affiliated to the Università della Svizzera italiana, and Humabs BioMed SA, a Swiss antibody therapeutics company, have identified, isolated and characterized two Ebola virus neutralizing monoclonal antibodies from the blood of a survivor of an Ebola infection.